Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-04
2008-08-12
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S278000, C514S279000, C514S409000, C514S410000, C514S413000, C514S414000
Reexamination Certificate
active
07410978
ABSTRACT:
A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
REFERENCES:
patent: 5273760 (1993-12-01), Oshlack
patent: 5837285 (1998-11-01), Nakamichi et al.
patent: 5962024 (1999-10-01), Marvola
patent: 5998430 (1999-12-01), Schwantes et al.
patent: 6156340 (2000-12-01), Adeyeye
patent: 6312726 (2001-11-01), Nakamichi et al.
patent: 6569462 (2003-05-01), Cornelli
patent: 6682759 (2004-01-01), Lim et al.
patent: 6905709 (2005-06-01), Oshlack
patent: 6923988 (2005-08-01), Patel et al.
patent: 6974820 (2005-12-01), Aberg
patent: 2002/0031550 (2002-03-01), Sauer
patent: 2003/0054032 (2003-03-01), Oshlack
patent: 2003/0064108 (2003-04-01), Lukas
patent: 2003/0185882 (2003-10-01), Vergez et al.
patent: 2003/0199480 (2003-10-01), Hayes
patent: 2004/0028729 (2004-02-01), Shojaei
patent: 2004/0202693 (2004-10-01), Chang
patent: 2004/0228917 (2004-11-01), Oshlack
patent: 2005/0009862 (2005-01-01), Sabounjian
patent: 2005/0043342 (2005-02-01), Aberg
patent: 2006/0047007 (2006-03-01), Danehower
patent: 1194422 (1963-03-01), None
patent: 1058542 (1967-02-01), None
patent: WO 2004/000280 (2003-12-01), None
patent: WO 2004/062577 (2004-07-01), None
patent: WO 2004/096125 (2004-11-01), None
Reitz et al., European Urology, 2004, 45, 510-515.
Junemann et al., Neurourology and Urodynamics, 1999, 18(4), 375-376.
Hofner et al., World J Urol, 2001, 19, 336-343.
Sigma Aldrich, online catalog, Hydroxypropyl methyl cellulose phthalate, Dec. 21, 2006.
Fusgen et al., Int J Clin Pharm Ther, 2000, 38(5), 223-234.
Garely et al., Expert Opinion on Pharmacotherapy, 2002, 3(7), 827-833.
Schröder S, Jetter A, Zaigler M, Weyhenmeyer R, Krumbiegel G, Wächter W, Fuhr U, entitled “Trospium Chloride Absorption From The Human Gastrointestinal Tract Assessed By Local Enteral Administration,”Eur. J. Clin. Pharmacol.(2002) 58, S97 (Poster demonstration 4th Annual Congr. on Clin. Pharmacol. Wiesbasden, Nov. 2002).
Schröder S, Jetter A, Zaigler M, Weyhenmeyer R, Krumbiegel G, Wächter W, Fuhr U, entitled “Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration,”International Journal of Clinical Pharmacology and Therapeutics, vol. 42, No. 10 (2004), pp. 543-549.
Langguth, P., et al., “Intestinal Absorption of the Quarternary Trospium Chloride: Permeability-Lowering factors and Bioavailabilities for Oral Dosage Forms”; European Journal of Pharmaceutics and Biopharmaceutics, El Sevier Science Publishers B.V., Amsterdam, NL, vol. 43, No. 3, Jun. 1997 (Jun. 1997), pp. 264-272.
European Patent Office Supplementary Search Report mailed Jan. 22, 2008 in EP 04 80 0569.
Bhatt Padmanabh
Flanner Henry H.
Kidane Argaw
Raoufinia Arash
Arent & Fox LLP
Richter Johann
Schlientz Nathan W
Supernus Pharmaceuticals, Inc.
LandOfFree
Once daily dosage forms of trospium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Once daily dosage forms of trospium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Once daily dosage forms of trospium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4005762